Viridian Therapeutics, Inc.\DE 8-K

What Happened

• On May 24, 2026, Viridian Therapeutics, Inc. announced it entered a Commercial Manufacturing Services Agreement with WuXi Biologics (Hong Kong) Limited for the manufacture and supply of veligrotug drug substance and drug product for commercial use, if approved. WuXi will be a non‑exclusive supplier and Viridian may use alternate manufacturers. The company said it will file the full agreement as an exhibit to its Form 10-Q for the quarter ended June 30, 2026.

Key Details

• Agreement date: May 24, 2026; initial term: 5 years with automatic successive 5‑year renewals unless 24 months’ notice of non‑renewal is given.
• Forecasts: Viridian will provide monthly rolling Forecasts; a portion of each Forecast is a binding, non‑cancellable commitment.
• Pricing and costs: Product service fee fixed through December 31, 2026; thereafter pricing may be adjusted annually based on volume; Viridian will reimburse certain pass‑through costs.
• Termination: Viridian may terminate on 30 days’ notice if changes in law materially impair WuXi’s performance; either party may terminate for uncured material breach or insolvency.

Why It Matters

• This agreement secures a commercial manufacturing partner for veligrotug, which is a key step toward commercial readiness if the product receives approval.
• The binding forecast commitments and multi‑year, auto‑renewing term create potential long‑term supply certainty but also contractual obligations that could affect costs and cash flow.
• Investors should review the full agreement in the upcoming 10‑Q to assess details on commitment volumes, pricing formulas, pass‑through costs, and any indemnities or liability provisions that could affect financials.